ExpreS2ion annual report for 2024 published

Hørsholm, Denmark, 1 May 2025 - ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the Annual Report for the financial year 2024 has been published. The Annual Report is available as an attachment to this press release and can be accessed on the Company’s website at: https://investor.expres2ionbio.com/reports/

The Annual Report provides a comprehensive overview of ExpreS2ion’s operational activities during 2024 and includes additional information regarding the Company’s full-year 2024 financial results. While the financial figures are consistent with those previously disclosed in the year-end report published in February 2025, the Annual Report contains expanded financial note disclosures and additional context on strategic and operational developments during the year.

The Swedish version of the Annual Report has been reviewed by the Company’s auditors, as confirmed in the Auditor’s Report included at the end of the document. In the event of discrepancies between the Swedish and English versions, the Swedish version shall prevail.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB

The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company’s news distributor, Cision, at the publication of this press release.

For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com 

About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.